Adoptive T Regulatory Cell Therapy for Tolerance Induction.
Adoptive T Regulatory Cell Therapy for Tolerance Induction.
复制标题
用于诱导耐受的过继性 T 调节细胞疗法。
DOI：
10.1007/s40472-015-0058-5
复制
发表时间：
2015
影响因子：
2.1
通讯作者：
Bayer,AllisonL
中科院分区：
文献类型：
--
作者：
Cabello-Kindelan,Cecilia;Mackey,Shane;Bayer,AllisonL
有一个明确的需要，以发展的战略，以诱导耐受，而不需要慢性免疫抑制移植受体和自身免疫性患者。免疫调节性T细胞（Treg）疗法提供了持久保护的潜力。然而，基于迄今为止使用离体扩增的自体Tregsin 1型糖尿病（T1D）患者的临床试验的结果，似乎不太可能使用Treginfusion而没有促进稳定供体Tregengraftment和持久性的免疫调节方案的单一免疫疗法将提供真正显著的临床益处。考虑Treg生成、稳态和功能所需的基本因素，联合治疗可以提供改善的结果，以促进长期供体Treg持续性，从而引起有益的治疗结果。
There is a clear need to develop strategies to induce tolerance without the need of chronic immunosuppression in transplant recipient and in patients with autoimmunity. Adoptive T regulatory cell (Treg) therapy offers the potential of long-lasting protection. However, based on results of clinical trials so far with ex vivo expanded autologous Tregsin type 1 diabetic (T1D) patients, it seems unlikely that single immunotherapy with Treginfusion without immunomodulation regimens that promote stable donor Tregengraftment and persistence would afford truly significant clinical benefit. Combination therapies could provide improved outcomes with consideration of the fundamental factors required for Treggeneration, homeostasis, and function to promote long-term donor Tregpersistence to provoke beneficial therapeutic outcomes.